Kestra Medical Technologies to Present at the Stifel 2025 Healthcare Conference
KIRKLAND, Wash., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital...
Day: October 28, 2025
REPEAT – MEDIA ADVISORY: Patients join Day of Action at Ontario Legislature to demand action on complaints about private clinics’ charges
TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- On Wednesday October 29, patients who have been wrongfully charged for surgeries and...
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the...
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreementTerumo to pay a...
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
Once-daily formulation of dexmethylphenidate achieved primary endpoint (p KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for...
ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts
UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation...
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting...
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with...
BioNTech to Host Innovation Series R&D Day on November 11, 2025
MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of...
Evidence Against Evidence: CERN-IEEE FPGA vs. Crosetto 3D-Flow, a Breakthrough Invention Recognized 32 Years Ago That Could Have, and Can Still, Save Billions of Euros and Millions of Lives
Science vs. Consensus: An urgent call to CERN, IEEE, and the scientific community to engage with verifiable evidence, fulfill scientific...
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net...
Context Therapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company...
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchisesOrders...
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in...
Cronos Brings Back Popular, Limited-Edition Spinach® Green Apple-Flavored Products for the Fall Season
Limited-Edition Spinach® Green Apple-Flavored Limited-Edition Spinach® Green Apple-Flavored TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON)...
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (Nasdaq: IVVD) is hosting the previously announced live...
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...
Causeway Therapeutics Debuts Positive Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis
Data Show Statistically Significant Improvements in Pain, Function and Tendon Structure in Appropriately Dosed PatientsGLASGOW, Scotland, Oct. 28, 2025 (GLOBE...
ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD
Approvals received from World Health Organization and United States Adopted Names Council establishing “xelafaslatide” as nonproprietary name for ONL1204 Ophthalmic...